Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Follicular 5Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 72Cisplatin 56Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × duvelisib × Clear all
NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

SecuraBio

Phase 1/2 Terminated
2 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡